Clinical evaluation of recombinant human growth hormone in Noonan syndrome
- PMID: 15004410
- DOI: 10.1507/endocrj.51.61
Clinical evaluation of recombinant human growth hormone in Noonan syndrome
Abstract
The objective of this study was to investigate the effect of administration of recombinant human growth hormone (hGH) in patients with Noonan syndrome. hGH was administered (0.5 IU/kg/week) to 15 patients with Noonan syndrome over a 2 year period. Average patient age prior to therapy was 7.5 +/- 2.5 (mean +/- SD) yr, the height SD score was -2.8 +/- 0.7, and the pretreatment height velocity and bone age were 4.8 +/- 1.0 cm/yr and 5.8 +/- 2.1 yr, respectively. The height velocity in the year prior to treatment, and 0-12 and 12-24 months after commencing treatment was 4.8 +/- 1.0 cm/yr, 7.0 +/- 1.2 cm/yr, and 5.5 +/- 0.6 cm/yr, respectively. The height velocity in the first year of treatment was significantly greater (P = 0.0001, n = 14) than the pretreatment value, but there was no significant difference in the second year. The height SD scores at the commencement of treatment, and after 12 and 24 months of treatment were -2.8 +/- 0.7, -2.4 +/- 0.7, and -2.2 +/- 0.5, respectively. Bone age advanced by 1.1 +/- 0.5 yr in the 12 months after commencing treatment. We conclude that the use of hGH may be beneficial in the treatment of Noonan syndrome, although further research is required.
Similar articles
-
Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone.J Clin Endocrinol Metab. 2009 Jul;94(7):2338-44. doi: 10.1210/jc.2008-2094. Epub 2009 Apr 28. J Clin Endocrinol Metab. 2009. PMID: 19401366
-
The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome.J Clin Endocrinol Metab. 1996 Jun;81(6):2291-7. doi: 10.1210/jcem.81.6.8964866. J Clin Endocrinol Metab. 1996. PMID: 8964866 Clinical Trial.
-
Growth hormone treatment in Noonan syndrome: report of four cases who reached final height.Horm Res. 1995;44(4):164-7. doi: 10.1159/000184618. Horm Res. 1995. PMID: 8522277 Clinical Trial.
-
The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence.Horm Res Paediatr. 2015;83(3):157-66. doi: 10.1159/000369012. Epub 2014 Dec 10. Horm Res Paediatr. 2015. PMID: 25503994 Review.
-
Recombinant growth hormone in children and adolescents with Turner syndrome.Cochrane Database Syst Rev. 2003;(3):CD003887. doi: 10.1002/14651858.CD003887. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003887. doi: 10.1002/14651858.CD003887.pub2. PMID: 12917993 Updated. Review.
Cited by
-
The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature.Int J Mol Sci. 2024 Sep 22;25(18):10169. doi: 10.3390/ijms251810169. Int J Mol Sci. 2024. PMID: 39337654 Free PMC article.
-
Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry.Int J Pediatr Endocrinol. 2012 Jun 8;2012(1):15. doi: 10.1186/1687-9856-2012-15. Int J Pediatr Endocrinol. 2012. PMID: 22682146 Free PMC article.
-
Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency.Ital J Pediatr. 2015 Oct 6;41:71. doi: 10.1186/s13052-015-0183-x. Ital J Pediatr. 2015. PMID: 26444854 Free PMC article.
-
Inside the Noonan "universe": Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns.Front Endocrinol (Lausanne). 2022 Aug 18;13:951331. doi: 10.3389/fendo.2022.951331. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36060964 Free PMC article. Review.
-
The Growth Characteristics of Patients with Noonan Syndrome: Results of Three Years of Growth Hormone Treatment: A Nationwide Multicenter Study.J Clin Res Pediatr Endocrinol. 2016 Sep 1;8(3):305-12. doi: 10.4274/jcrpe.3013. Epub 2016 Apr 29. J Clin Res Pediatr Endocrinol. 2016. PMID: 27125300 Free PMC article.
